Cutia Therapeutics (HK:2487) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cutia Therapeutics, a R&D-driven biopharmaceutical company, has reported a significant 178.3% revenue increase in the first half of 2024 compared to the same period in 2023. The company’s gross profit margin also improved by 5 percentage points, reaching 53%. These financial gains coincide with advances in their dermatology-focused product pipeline, including new treatments for scalp and skin conditions and a range of commercialization milestones.
For further insights into HK:2487 stock, check out TipRanks’ Stock Analysis page.